EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Estimation of vaccine effectiveness against SARS-CoV-2-associated hospitalization using sentinel surveillance in South Africa

Nicola Chiwandire iD, Sibongile Walaza, Anne von Gottberg, Nicole Wolter iD, Mignon Du Plessis, Fahima Moosa, Michelle J Groome, Jeremy Nel, Ebrahim Variava, Halima Dawood, Mvuyo Makhasi, Leora R Feldstein und 4 weitere

International Journal of Epidemiology · 2024

DOI: 10.1093/ije/dyae116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Epidemiology, 2024. Verfasst von Nicola Chiwandire und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of the National Health Laboratory Service, National Institute for Communicable Diseases, Johannesburg, South Africa. Hauptthemen laut MEDLINE: COVID-19, Hospitalization, Vaccine Efficacy, Sentinel Surveillance. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust, Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

COVID-19 vaccine effectiveness (VE) studies leveraging systematic surveillance in sub-Saharan Africa are limited. We assessed the effectiveness of two vaccines (Pfizer BNT162b2 and Johnson & Johnson Ad26.COV2.S) against SARS-CoV-2-associated hospitalization in South African adults aged ≥18 years.

Methods

We conducted a test-negative case-control study using pneumonia surveillance data in South Africa. Inpatients with physician-diagnosed lower respiratory tract infection or suspected COVID-19, testing SARS-CoV-2 positive or negative from June 2021–March 2022, were cases or controls, respectively. Fully vaccinated individuals received one Ad26.COV2.S dose or two BNT162b2 doses ≥14-days before enrollment. VE was estimated using multivariable logistic regression for Delta- and Omicron BA.1/BA.2-predominant periods, stratified by age and HIV status.

Results

The study included 925 cases and 1890 controls; 38 (4%) cases and 186 (10%) controls were fully vaccinated with BNT162b2, and 30 (3%) cases and 94 (5%) controls with Ad26.COV2.S. The vaccine effectiveness of BNT162b2 against SARS-CoV-2-associated hospitalization over Delta and Omicron BA.1/BA.2 periods was 91% (95% CI: 52%, 98%) and 33% (-16%, 86%), respectively. The vaccine effectiveness of Ad26.COV2.S against hospitalization over Delta and Omicron BA.1/BA.2 periods was 72% (-36% ,94%), and -19% (-130%, 39%), respectively. The vaccine effectiveness of BNT162b2 against hospitalization over the Delta period was 94% (50%, 99%) and 89% (27%, 98%) among adults aged ≥60 years and HIV-uninfected, respectively.

Conclusions

The BNT162b2 vaccine was effective against SARS-CoV-2-associated hospitalization during the Delta period for adults aged ≥18 years, ≥60 years and those HIV-uninfected. VE for Ad26.COV2.S was inconclusive, potentially due to limited sample size or residual confounding. These findings highlight the utility of sentinel surveillance for estimating VE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HospitalizationVaccine EfficacySentinel SurveillanceSARS-CoV-2HumansSouth AfricaMaleFemaleAdultMiddle AgedCase-Control StudiesYoung AdultAdolescentCOVID-19 VaccinesAgedBNT162 VaccineAd26COVS1

Stichwörter der Autor:innen

COVID-19SARS-CoV-2sentinel surveillancetest-negative case controlvaccine effectiveness

Substanzen

COVID-19 VaccinesBNT162 VaccineAd26COVS1

Autor:innen und Institutionen

  • Division of the National Health Laboratory Service, National Institute for Communicable Diseases, Johannesburg, South Africa.
  • School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Department of Medicine, Klerksdorp-Tshepong Hospital Complex, Klerksdorp, South Africa.
  • Department of Medicine, Greys Hospital, Pietermaritzburg, South Africa.

ORCID-Profile: Nicola Chiwandire, Nicole Wolter, Perrine Marcenac

Förderung

  • Wellcome Trust
  • Gates Foundation

Zitieren

APA

Chiwandire, N., Walaza, S., von Gottberg, A., Wolter, N., Du Plessis, M., Moosa, F., Groome, M. J., Nel, J., Variava, E., Dawood, H., Makhasi, M., Feldstein, L. R., Marcenac, P., Lafond, K. E., Samuels, A. M., & Cohen, C. (2024). Estimation of vaccine effectiveness against SARS-CoV-2-associated hospitalization using sentinel surveillance in South Africa. International Journal of Epidemiology. https://doi.org/10.1093/ije/dyae116

Vancouver

Chiwandire N, Walaza S, von Gottberg A, Wolter N, Du Plessis M, Moosa F, et al. Estimation of vaccine effectiveness against SARS-CoV-2-associated hospitalization using sentinel surveillance in South Africa. International Journal of Epidemiology. 2024. doi:10.1093/ije/dyae116

BibTeX
@article{Chiwandire2024,
  author = {Chiwandire, Nicola and Walaza, Sibongile and von Gottberg, Anne and Wolter, Nicole and Du Plessis, Mignon and Moosa, Fahima and Groome, Michelle J and Nel, Jeremy and Variava, Ebrahim and Dawood, Halima and Makhasi, Mvuyo and Feldstein, Leora R and Marcenac, Perrine and Lafond, Kathryn E and Samuels, Aaron M and Cohen, Cheryl},
  title = {Estimation of vaccine effectiveness against SARS-CoV-2-associated hospitalization using sentinel surveillance in South Africa},
  journal = {International Journal of Epidemiology},
  year = {2024},
  doi = {10.1093/ije/dyae116}
}
Kostenlos starten →